JPWO2021194672A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021194672A5 JPWO2021194672A5 JP2022558088A JP2022558088A JPWO2021194672A5 JP WO2021194672 A5 JPWO2021194672 A5 JP WO2021194672A5 JP 2022558088 A JP2022558088 A JP 2022558088A JP 2022558088 A JP2022558088 A JP 2022558088A JP WO2021194672 A5 JPWO2021194672 A5 JP WO2021194672A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoemulsion
- nanoemulsion composition
- virus
- composition according
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007908 nanoemulsion Substances 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 58
- 239000004094 surface-active agent Substances 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 27
- 239000012867 bioactive agent Substances 0.000 claims description 18
- 230000002209 hydrophobic effect Effects 0.000 claims description 18
- 239000002105 nanoparticle Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 9
- -1 cationic lipid Chemical class 0.000 claims description 9
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- 241001493065 dsRNA viruses Species 0.000 claims description 5
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims description 4
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims description 4
- 241000609532 mosquito-borne viruses Species 0.000 claims description 4
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 3
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 3
- 239000004147 Sorbitan trioleate Substances 0.000 claims description 3
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000002296 dynamic light scattering Methods 0.000 claims description 3
- 229910000000 metal hydroxide Inorganic materials 0.000 claims description 3
- 150000004692 metal hydroxides Chemical class 0.000 claims description 3
- 229910044991 metal oxide Inorganic materials 0.000 claims description 3
- 150000004706 metal oxides Chemical class 0.000 claims description 3
- 239000001593 sorbitan monooleate Substances 0.000 claims description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 3
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 3
- 239000001587 sorbitan monostearate Substances 0.000 claims description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 3
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 3
- 235000019337 sorbitan trioleate Nutrition 0.000 claims description 3
- 229960000391 sorbitan trioleate Drugs 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 claims description 2
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- GZWGEAAWWHKLDR-JDVCJPALSA-M dimethyl-bis[(z)-octadec-9-enoyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)[N+](C)(C)C(=O)CCCCCCC\C=C/CCCCCCCC GZWGEAAWWHKLDR-JDVCJPALSA-M 0.000 claims description 2
- XSWSEQPWKOWORN-UHFFFAOYSA-N dodecan-2-ol Chemical compound CCCCCCCCCCC(C)O XSWSEQPWKOWORN-UHFFFAOYSA-N 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 229910001463 metal phosphate Inorganic materials 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 claims 5
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 claims 5
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- 239000003921 oil Substances 0.000 claims 4
- 235000019198 oils Nutrition 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241001678559 COVID-19 virus Species 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 235000019486 Sunflower oil Nutrition 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 241000907316 Zika virus Species 0.000 claims 1
- 239000010775 animal oil Substances 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 239000008169 grapeseed oil Substances 0.000 claims 1
- 229910052595 hematite Inorganic materials 0.000 claims 1
- 239000011019 hematite Substances 0.000 claims 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 claims 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 150000002759 monoacylglycerols Chemical class 0.000 claims 1
- 239000004006 olive oil Substances 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 239000003549 soybean oil Substances 0.000 claims 1
- 235000012424 soybean oil Nutrition 0.000 claims 1
- 239000002600 sunflower oil Substances 0.000 claims 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 239000000427 antigen Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 229940044606 RIG-I agonist Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062993307P | 2020-03-23 | 2020-03-23 | |
US62/993,307 | 2020-03-23 | ||
US202063054754P | 2020-07-21 | 2020-07-21 | |
US63/054,754 | 2020-07-21 | ||
PCT/US2021/019103 WO2021194672A1 (fr) | 2020-03-23 | 2021-02-22 | Compositions et procédés pour l'administration d'arn |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023518976A JP2023518976A (ja) | 2023-05-09 |
JPWO2021194672A5 true JPWO2021194672A5 (fr) | 2024-02-08 |
Family
ID=74885039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022558088A Pending JP2023518976A (ja) | 2020-03-23 | 2021-02-22 | Rnaを送達するための組成物および方法 |
Country Status (10)
Country | Link |
---|---|
US (13) | US20220110881A1 (fr) |
EP (1) | EP4126021A1 (fr) |
JP (1) | JP2023518976A (fr) |
KR (1) | KR20220156933A (fr) |
CN (1) | CN115551548A (fr) |
AU (1) | AU2021241355A1 (fr) |
BR (1) | BR112022019124A2 (fr) |
CA (1) | CA3172489A1 (fr) |
GB (2) | GB2605538A (fr) |
WO (1) | WO2021194672A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
CN115551548A (zh) | 2020-03-23 | 2022-12-30 | 赫德特生物公司 | 用于rna递送的组合物和方法 |
US20220193225A1 (en) * | 2020-08-31 | 2022-06-23 | Bruce Lyday | Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins |
WO2023133500A2 (fr) * | 2022-01-07 | 2023-07-13 | Hdt Bio Corp. | Compositions et méthodes associées à des réponses immunitaires multivalentes |
WO2023228116A1 (fr) * | 2022-05-24 | 2023-11-30 | Access To Advanced Health Institute | Administration intranasale de vaccins à arn thermostables |
WO2024031051A1 (fr) | 2022-08-05 | 2024-02-08 | Life Technologies Corporation | Lipides pour l'administration d'acides nucléiques |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8206749B1 (en) | 1999-02-26 | 2012-06-26 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
AU7398200A (en) | 1999-09-17 | 2001-04-24 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
WO2002080982A2 (fr) | 2001-01-12 | 2002-10-17 | Chiron Corporation | Immunisation des muqueuses par acide nucleique |
AU2002327614B2 (en) | 2001-09-06 | 2007-12-06 | Alphavax, Inc. | Alphavirus replicon vector systems |
US7416840B2 (en) | 2002-12-13 | 2008-08-26 | Fox Chase Cancer Center | Replication of hepatitis C virus in non-hepatic epithelial and mouse hepatic cells |
EP1673470A2 (fr) | 2003-09-18 | 2006-06-28 | Genmab A/S | Polypeptides specifiques de tumeur d'expression differentielle utilisables pour le diagnostic et le traitement du cancer |
MXPA06013124A (es) | 2004-05-18 | 2007-05-23 | Alphavax Inc | Vectores de alfavirus derivados de tc-83, particulas y metodos. |
TWI388344B (zh) | 2005-08-23 | 2013-03-11 | Celsion Corp | 儲存奈米微粒調合物之方法 |
BRPI0716959A2 (pt) | 2006-09-26 | 2013-10-29 | Infectious Disease Res Inst | Composição de vacina contendo adjuvante sintético |
PL2136836T3 (pl) | 2007-04-04 | 2017-07-31 | Infectious Disease Research Institute | Kompozycje immunogenne zawierające polipeptydy prątka gruźlicy i produkty ich fuzji |
US9446150B2 (en) * | 2007-10-09 | 2016-09-20 | Washington University | Particles for imaging |
CN102428174A (zh) | 2009-02-24 | 2012-04-25 | 斯克利普斯研究所 | 工程再造mRNA一级结构以增强蛋白质产生 |
EP3124491B1 (fr) | 2009-06-05 | 2019-10-30 | Infectious Disease Research Institute | Adjuvants lipidiques synthétiques à base de glucopyranosyle et compositions de vaccin ainsi que compositions pharmaceutiques les contenant |
EA036522B1 (ru) | 2009-12-11 | 2020-11-19 | Пфайзер Инк. | Фармацевтическая композиция, пригодная для лиофилизации, содержащая множество терапевтических частиц |
WO2011156761A1 (fr) | 2010-06-10 | 2011-12-15 | University Of Washington Through Its Center For Commercialization | Procédés et systèmes pour l'interaction de l'adénovirus avec la desmogléine 2 (dsg2) |
US9555136B2 (en) | 2010-06-21 | 2017-01-31 | University Of Washington Through Its Center For Commercialization | Coated magnetic nanoparticles |
BR112013000391B8 (pt) | 2010-07-06 | 2022-10-04 | Novartis Ag | Composição de emulsão catiônica de óleo em água e seu uso |
BR112014000227A8 (pt) | 2011-07-06 | 2018-03-06 | Novartis Ag | emulsões óleo-em-água que contêm ácidos nucleicos |
EP4299138A2 (fr) | 2012-08-03 | 2024-01-03 | Access to Advanced Health Institute | Compositions et méthodes de traitement d'une infection active par le bacille de koch |
US20160000886A1 (en) | 2013-02-22 | 2016-01-07 | President And Fellows Of Harvard College | Nanostructured active therapeutic vehicles and uses thereof |
US9775894B2 (en) | 2013-07-09 | 2017-10-03 | University Of Washington Through Its Center For Commercialization | Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling |
EP3915579A1 (fr) | 2013-12-31 | 2021-12-01 | Infectious Disease Research Institute | Formulations de vaccin à flacon unique |
RU2746406C2 (ru) | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот |
CA2973943A1 (fr) | 2015-01-16 | 2016-07-21 | National Institute Of Advanced Industrial Science And Technology | Systeme d'expression genique mettant en uvre un arn furtif, et vecteur d'introduction/expression de gene comprenant ledit arn |
RU2749113C2 (ru) | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
CN106176599A (zh) | 2015-05-06 | 2016-12-07 | 江苏天士力帝益药业有限公司 | 一种卡巴他赛脂肪乳注射剂及其制备方法 |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
CN106445676B (zh) * | 2015-08-05 | 2019-10-22 | 杭州海康威视系统技术有限公司 | 一种分布式数据计算的任务分配方法和任务分配装置 |
US10780099B2 (en) | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
EP3364950A4 (fr) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Vaccins contre des maladies tropicales |
DE102017206254A1 (de) | 2016-04-13 | 2017-10-19 | Dialog Semiconductor (Uk) Limited | DC-DC-Umwandlung für Mehrzellen-Batterien |
JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
JP7195148B2 (ja) | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Tlrアゴニストを含有する製剤及び使用方法 |
JP7195147B2 (ja) | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Peg化リポソームおよび使用方法 |
US20200148729A1 (en) | 2016-05-21 | 2020-05-14 | Infectious Disease Research Institute | Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections |
WO2017210364A1 (fr) | 2016-06-01 | 2017-12-07 | Infectious Disease Research Institute | Nanoparticules d'alun contenant un agent d'encollage |
EP3468537A1 (fr) | 2016-06-14 | 2019-04-17 | Modernatx, Inc. | Formulations stabilisées de nanoparticules lipidiques |
WO2018022957A1 (fr) * | 2016-07-29 | 2018-02-01 | Tarveda Therapeutics, Inc. | Conjugués de liaison aux lymphocytes t et méthodes d'utilisation associées |
KR20180025701A (ko) | 2016-09-01 | 2018-03-09 | (주)아모레퍼시픽 | 특정 siRNA을 포함하는 멜라닌 증진용 조성물 |
US11801290B2 (en) | 2016-09-16 | 2023-10-31 | Access To Advanced Health Institute | Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy |
BR112019007433A2 (pt) | 2016-10-17 | 2019-07-02 | Synthetic Genomics Inc | sistemas de replicon de vírus recombinante e usos dos mesmos |
WO2018147710A1 (fr) | 2017-02-13 | 2018-08-16 | 단디바이오사이언스 주식회사 | Nanoémulsion comprenant une matière à base d'imidazoquinoline et son utilisation |
JP2020524143A (ja) | 2017-06-15 | 2020-08-13 | インフェクシャス ディズィーズ リサーチ インスティチュート | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
WO2019140001A1 (fr) | 2018-01-09 | 2019-07-18 | Vanderbilt University | Promédicaments agonistes du récepteur de reconnaissance de motif et leurs procédés d'utilisation |
AU2019210189A1 (en) | 2018-01-19 | 2020-08-06 | Janssen Pharmaceuticals, Inc. | Induce and enhance immune responses using recombinant replicon systems |
CN111836623A (zh) | 2018-02-02 | 2020-10-27 | 华盛顿大学 | 诱导三重基序包含蛋白16(trim16)信号传导的组合物和方法 |
JP2022515782A (ja) | 2018-12-19 | 2022-02-22 | ニュークレイン リミテッド ライアビリティ カンパニー | 分子診断のための装置および方法 |
US20200224174A1 (en) | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Methods for in vitro evolution of constructs derived from viruses |
US11406699B2 (en) | 2019-03-22 | 2022-08-09 | George Mason University | Alphavirus and compositions, methods, and kits related thereto |
CN114340665A (zh) | 2019-05-25 | 2022-04-12 | 传染病研究所 | 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法 |
GB201908729D0 (en) | 2019-06-18 | 2019-07-31 | Imp College Innovations Ltd | RNA construct |
CA3145278A1 (fr) | 2019-07-26 | 2021-02-04 | Vanderbilt University | Anticorps monoclonaux humains diriges contre l'enterovirus d68 |
JP7154425B2 (ja) * | 2019-09-02 | 2022-10-17 | 東芝三菱電機産業システム株式会社 | 電力変換装置及び電動機ドライブシステム |
US11679163B2 (en) * | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
EP4037706A4 (fr) | 2019-10-02 | 2023-09-13 | University of Washington | Compositions et méthodes de traitement d'une infection par le virus de l'hépatite b |
WO2021072112A1 (fr) | 2019-10-09 | 2021-04-15 | Hdt Bio Corp. | Détection de la desmogléine 2 dans les cancers d'origine épithéliale |
KR20210046316A (ko) * | 2019-10-18 | 2021-04-28 | 현대모비스 주식회사 | 사이드 에어백 장치 |
IL295548A (en) | 2020-02-14 | 2022-10-01 | Altimmune Inc | Immunogenic compositions of the corona virus and their uses |
WO2021178416A1 (fr) | 2020-03-02 | 2021-09-10 | Heat Biologics, Inc. | Traitements d'infections à coronavirus à médiation immunitaire |
US11478543B1 (en) | 2020-03-06 | 2022-10-25 | Thomas Jefferson University | Coronavirus disease (COVID-19) vaccine |
JP2023519173A (ja) | 2020-03-09 | 2023-05-10 | アークトゥラス・セラピューティクス・インコーポレイテッド | 免疫応答を誘導するための組成物及び方法 |
CN115551548A (zh) | 2020-03-23 | 2022-12-30 | 赫德特生物公司 | 用于rna递送的组合物和方法 |
CN115867658A (zh) | 2020-04-17 | 2023-03-28 | Vlp治疗公司 | 冠状病毒疫苗 |
US20230310323A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
KR20230148148A (ko) | 2020-12-23 | 2023-10-24 | 액세스 투 어드밴스드 헬스 인스티튜트 | 솔라네솔 백신 보조제 및 이의 제조 방법 |
KR20240035836A (ko) | 2021-07-13 | 2024-03-18 | 젠노바 바이오파마슈티컬스 리미티드 | 지질 나노-에멀젼 입자에 흡착된 rna 및 그 제제 |
WO2023026301A1 (fr) | 2021-08-25 | 2023-03-02 | Gennova Biopharmaceuticals Ltd. | Formulations lyophilisées d'arnm adsorbés sur des particules de nano-émulsion lipidique |
WO2023049363A1 (fr) | 2021-09-24 | 2023-03-30 | Amgen Inc. | Sotorasib et afatinib pour le traitement du cancer comprenant une mutation kras g12c |
-
2021
- 2021-02-22 CN CN202180035370.7A patent/CN115551548A/zh active Pending
- 2021-02-22 GB GB2208979.1A patent/GB2605538A/en active Pending
- 2021-02-22 BR BR112022019124A patent/BR112022019124A2/pt unknown
- 2021-02-22 AU AU2021241355A patent/AU2021241355A1/en active Pending
- 2021-02-22 CA CA3172489A patent/CA3172489A1/fr active Pending
- 2021-02-22 JP JP2022558088A patent/JP2023518976A/ja active Pending
- 2021-02-22 WO PCT/US2021/019103 patent/WO2021194672A1/fr unknown
- 2021-02-22 GB GB2208100.4A patent/GB2605312A/en active Pending
- 2021-02-22 KR KR1020227036829A patent/KR20220156933A/ko unknown
- 2021-02-22 EP EP21712624.2A patent/EP4126021A1/fr active Pending
- 2021-11-10 US US17/523,442 patent/US20220110881A1/en not_active Abandoned
- 2021-11-10 US US17/523,450 patent/US11458209B2/en active Active
- 2021-11-10 US US17/523,568 patent/US11376335B2/en active Active
- 2021-11-10 US US17/523,457 patent/US11318213B2/en active Active
-
2022
- 2022-03-23 US US17/702,730 patent/US11433142B2/en active Active
- 2022-04-19 US US17/723,779 patent/US11534497B2/en active Active
- 2022-06-14 US US17/839,574 patent/US11752218B2/en active Active
- 2022-07-29 US US17/876,824 patent/US11559584B2/en active Active
- 2022-08-22 US US17/821,445 patent/US11648321B2/en active Active
- 2022-11-22 US US18/057,833 patent/US11648322B2/en active Active
- 2022-12-05 US US18/061,725 patent/US11654200B2/en active Active
-
2023
- 2023-07-24 US US18/357,280 patent/US11896677B2/en active Active
- 2023-12-20 US US18/390,700 patent/US20240115728A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11318213B2 (en) | Compositions and methods for delivery of RNA | |
Couvreur et al. | Nanotechnology: intelligent design to treat complex disease | |
Buse et al. | Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances | |
del Pozo-Rodríguez et al. | Lipid nanoparticles as vehicles for macromolecules: nucleic acids and peptides | |
Morales-Becerril et al. | Nanocarriers for delivery of siRNA as gene silencing mediator | |
JPWO2021194672A5 (fr) | ||
Rastogi et al. | Role of stealth lipids in nanomedicine-based drug carriers | |
US11679163B2 (en) | Compositions and methods for delivery of RNA | |
Pranatharthiharan et al. | Inorganic nanovectors for nucleic acid delivery | |
Ongun et al. | Lipid nanoparticles for local delivery of mRNA to the respiratory tract: Effect of PEG-lipid content and administration route | |
Tu et al. | Lipids and their derivatives: by-products used as essential building blocks for modern drug delivery systems | |
WO2023049777A2 (fr) | Compositions agonistes de capteur d'acide nucléique et leurs utilisations | |
WO2023133500A2 (fr) | Compositions et méthodes associées à des réponses immunitaires multivalentes | |
AL-Deen | On the Delivery of Blood Stage Malaria DNA Vaccine Using Magnetic Nanoparticles | |
Nawwab Al-Deen | On the delivery of blood stage malaria DNA vaccine using magnetic nanoparticles | |
Wei et al. | Microspheres for Targeting Delivery of Anticancer Drugs | |
NANOCARRIERS | FOR DRUG DELIVERY |